Clinical Trial Search

Primary: Baseline-to-Exit Change in Drinks Per Drinking Day (TLFB) — -1.98; -2.82; -1.22 Standard Drinks per Drinking Day

Primary: Correlation of Tumor-informed CAPP-Seq ctDNA Analysis With Radiologic Tumor Assessments — 100; 66; 100; NA Percent Accuracy

Primary: Percent Change in Neocortical [11C]Cimbi-36 BPND From Baseline to Intervention in Each Arm — 7.4; 0.6; 3.8 percent change

Primary: Part A: Number of Patients With Dose Limiting Toxicities (DLTs) in the MTD Evaluation Period — 1; 0; 2 Participants

Primary: Four Square Step Test — 9.91; 10.17; 8.93; 9.50 seconds

Primary: Cardiac Rehabilitation Attendance — 16.9; 12.0; 24.1; 10.9 sessions of CR

Primary: Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria — 7.1; 10.2; 5.7; 9.6 months

Primary: Number of Data Updates Received by the uCor Subject Management System — 3 data updates per subject

Primary: Number of Participants With Postoperative Urinary Retention (POUR) of Sugammadex and Neostigmine Groups — 20; 6 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 13 Participants

Primary: Percent Change From Baseline in Total Abscess and Inflammatory Nodule Count at Week 12 — -34.7; -38.8 percent change

Primary: Change in Pain Disability - Roland Morris Disability Questionnaire (RMDQ) Score — 8.7; 10.1; 6.4 score on a scale

Primary: Alcohol-induced Change in Receptor Availability — -9.1 percentage change of BP_ND

Primary: Occurrence of Treatment Emergent Adverse Events (AEs) — 18; 12 Participants

Primary: Operative Time — 36; 37 minutes